FY2026 EPS Estimates for Esperion Therapeutics, Inc. Cut by Analyst (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research decreased their FY2026 earnings per share estimates for Esperion Therapeutics in a report released on Monday, May 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of $1.44 for the year, down from their prior estimate of $1.81. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the previous year, the company earned ($0.76) earnings per share.

Several other research firms have also weighed in on ESPR. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Trading Down 13.9 %

Shares of ESPR opened at $2.04 on Wednesday. The firm has a market cap of $386.38 million, a price-to-earnings ratio of -0.96 and a beta of 0.89. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The stock has a 50 day moving average of $2.31 and a 200-day moving average of $2.07.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Spire Wealth Management boosted its stake in shares of Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $30,000. Herbst Group LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter worth $28,000. Summit Financial LLC raised its position in Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 10,355 shares during the period. Finally, PSI Advisors LLC lifted its stake in Esperion Therapeutics by 161.5% in the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 10,500 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.